Site Map
Pages
- About us
- Ambassadors
- Annual reports and accounts
- Bloomhill Cancer Care
- Contact us
- Leukaemia Foundation Position Statements
- Blood Stem Cell and Bone Marrow Donations For Allogeneic Transplants Position Statement
- Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Position Statement
- Coronavirus Vaccines Position Statement
- Flu Season and Flu Vaccines Position Statement
- Glyphosate Position Statement
- Medicinal Cannabis Position Statement
- Research Involving Animals Position Statement
- Voice to Parliament Position Statement
- Voluntary Assisted Dying Position Statement
- Our people
- Our Reconciliation Action Plan
- ReACH program
- Working with us
- QIP Accredited
- Advocacy and policy
- About the National Strategic Action Plan for Blood Cancer
- Blood Cancer Taskforce
- Federal Election 2025: Priorities for Blood Cancer
- Leukaemia Foundation policy submissions
- National Strategic Action Plan for Blood Cancer
- Our Submissions to MSAC and PBAC
- State of the Nation: Blood Cancers in Australia
- Working with Governments
- Blood cancer information
- Blood cancer and culturally and linguistically diverse (CaLD) people
- Blood cancer and First Nations peoples
- Blood cancer and LGBTQIA+ people
- Blood cancer signs and symptoms
- Carers and friends
- Common Side Effects of Blood Cancer and its treatment
- Diseases we support
- For healthcare professionals
- Immunotherapies and Targeted therapies
- Information for CaLD, First Nations and LGBTQIA+ people
- Living well with blood cancer
- Optimal Care Pathways
- Healthcare Professional Optimal Care Pathways
- Optimal Care Pathways for AL-amyloidosis – HCP
- Optimal Care Pathways for leukaemia – HCP
- Optimal Care Pathways for lymphoma – HCP
- Optimal Care Pathways for myelodysplastic syndromes (MDS) – HCP
- Optimal Care Pathways for myeloma – HCP
- Optimal Care Pathways for myeloproliferative neoplasms (MPN) – HCP
- Patient Optimal Care Pathways
- Optimal Care Pathways for AL-amyloidosis patients
- Optimal Care Pathways for leukaemia patients
- Optimal Care Pathways for lymphoma patients
- Optimal Care Pathways for myelodysplastic syndromes (MDS) patients
- Optimal Care Pathways for myeloma patients
- Optimal Care Pathways for myeloproliferative neoplasms (MPN) patients
- Healthcare Professional Optimal Care Pathways
- Real stories
- The blood cancer journey
- Understanding your blood
- Blood cancer and COVID-19
- Types of blood cancer
- Amyloidosis
- Aplastic anaemia
- Childhood blood cancers
- Leukaemia
- Lymphoma
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Non-Hodgkin lymphoma diagnosis
- Non-Hodgkin lymphoma treatment
- Side effects of non-Hodgkin lymphoma treatment
- Adult T-cell lymphoma
- Anaplastic large cell lymphoma
- Burkitt’s lymphoma
- Diffuse large B-cell lymphoma
- Double hit lymphoma
- Follicular lymphoma
- Lymphoblastic lymphoma
- Mantle cell lymphoma
- Mucosa-associated lymphoid tissue lymphoma
- Nodal marginal zone lymphoma
- Peripheral T-cell lymphoma
- Primary central nervous system lymphoma
- Skin lymphomas
- Small lymphocytic lymphoma
- Myelodysplastic neoplasms (MDS)
- Myeloma
- Myeloproliferative neoplasms (MPN)
- Waldenstrom’s macroglobulinaemia (WM)
- Disclaimer
- Fundraise
- Get involved
- Become a member
- Blood Cancer Month
- Blood stem cell (bone marrow) donation
- Business partnerships
- Common blood cancer signs and symptoms – content toolkit
- Consumer engagement program
- Events
- Lifetime Giving Circles
- Myeloma Awareness Month
- Other ways to get involved
- Volunteer
- World Blood Cancer Day
- World Lymphoma Awareness Day
- World’s Greatest Shave 2025
- World’s Greatest Shave Digital Toolkit
- Glossary of common terms
- Home
- How we can help
- Accommodation services
- About our accommodation services
- Bridgestone Australia Blood Cancer Centre (Adelaide)
- Clem Jones – Sunland Blood Cancer Centre (Brisbane)
- ESA Blood Cancer Centre (Brisbane)
- John James Blood Cancer Centre (Canberra)
- Melbourne Blood Cancer Centre (Melbourne)
- NSW Accommodation
- Phillip Desbrow Blood Cancer Centre (Brisbane)
- Policies and reimbursements
- Queensland Freemasons Blood Cancer Centre (Townsville)
- Stirling Cross Blood Cancer Centre (Perth)
- Village Green Blood Cancer Centre (Brisbane)
- What we are doing to keep our residents safe
- Assessment and referral services
- Emotional support services
- Financial Information
- Grief and bereavement support services
- Health and wellbeing support services
- Healthcare service directory
- Information and education services
- Information and support service referral
- Online Blood Cancer Support Service
- Online education and support
- Practical support services
- Support for blood cancer patients outside Australia
- Support research with your own blood cancer story
- Transport services
- Accommodation services
- Make a donation
- News
- Notification statement
- Privacy
- Regular Giving Service Agreement
- Research
- Current funding opportunities
- Leukaemia Foundation Alumni Program
- National Research Program
- Cancer Australia PdCCRS recipients
- Can we prevent relapse in children with leukaemia by using natural killer cells found in umbilical cord blood?
- Developing a new drug a as a novel therapeutic strategy for aggressive leukaemia in children
- Developing a new targeted therapy with minimal side effects and toxicity to improve the outcome of childhood AML
- Developing new models for drug testing to understand the biology and mechanisms of drug resistance in AML
- Dr Gabriela Brumatti: Using novel combination therapy to increase the chances of cure for childhood AML
- Dr Hannah Wardill: Harnessing the power of the microbiome to prevent GvHD in children after a stem cell transplant
- Dr Kate Vandyke: Increasing the efficiency while decreasing toxicity of myeloma therapies
- Dr Kyohei Nakamura: Using immunotherapy to improve lymphoma outcomes
- Dr Laurence Cheung: Studying the interaction between bone and leukaemia cells to improve treatment outcomes in childhood leukaemia
- Dr Melissa Cantley: Developing new tests to identify which individuals with smouldering myeloma are at risk of developing myeloma
- Dr Rachel Thijssen: Understanding more about why people with chronic lymphocytic leukaemia can become resistant to treatment
- Kate Vandyke: Is it possible to predict myeloma risk by looking at factors produced by ageing bone marrow cells?
- Clinical trials
- Blood Cancer Genomics Trial
- New trial offers renewed hope to children and young adults with ALL
- The Trials Enabling Program (TEP)
- Clinical trial comparing allogeneic stem cell transplants vs best available non-transplant therapies for myelofibrosis
- Clinical trial for Advanced Stage Hodgkin Lymphoma
- Clinical trial for high tumour burden follicular lymphoma
- Clinical trial for newly diagnosed AML or MDS with FLT3 mutation
- Clinical trial for newly diagnosed AML or MDS with IDH1 or IDH2 mutation
- Trials Enabling Program FAQs
- PhD scholarship recipients
- Advancing the effective use of targeted therapies for blood cancers while reducing side effects
- Basit Salik: Targeting the cancer-immune crosstalk in AML
- Dr Jasmine Singh: Clonal haematopoiesis of indeterminate potential (CHIP) – what does it mean?
- Dr Julian Grabek: Identifying subclones in early phase MPN that drive progression and leukaemic transformation
- Dr Karthik Nath: Using genetic and molecular technologies to better understand follicular lymphoma
- Dr Khai Li Chai: Evaluating the evidence base, current practice and clinical outcomes of immunoglobulin treatment
- Dr Liesl Butler: Investigating the gene mutations and biological pathways that lead to the development of MPNs
- Dr Ray Koo: Improving outcomes for patients after donated stem cell transplants
- Dr Vajiranee Malalasekera: Investigating mechanisms of disease development and new therapies in AML with high-risk genetic alternations
- Dr Wei Jiang: T-cell immunotherapy for B-cell malignancies and viral infections
- Elizabeth Lieschke: Investigating the mechanisms by which Tp53 prevents the development of leukaemia, lymphoma
- Getting under the skin of T-cell disorders
- Improving treatment of blood cancers using targeted therapies
- Julian Lindsay: Using antifungal treatments to prevent infection in people with blood cancers and those undergoing bone marrow transplants
- Prolonging remission using early relapse warning system
- Understanding why some Lymphomas are resistant to CAR-T therapy
- Strategic Ecosystem Partnership Grant recipients
- Assoc. Prof Daniel Gray: Deep profiling of ALL and myeloma for targeted therapies
- Assoc. Prof. Anna Brown: Developing state-of-the art molecular genomic testing in cancer diagnosis and monitoring
- Assoc. Prof. Melissa Call: Improving the Safety and Efficacy of Chimeric Antigen Receptor (CAR) T Cell Therapies
- Dr Devendra Hiwase: Impact of Frailty on Treatment and healthcare: improving quality of life for older MDS/AML patients
- Dr Zachary Hunter: Multiomic analysis in Waldenstrom’s Macroglobulinemia
- High-precision testing of single cells with cutting-edge imaging
- Prof. Deb White: Precision Medicine and the gut microbiome in ALL
- Prof. Jake Shortt: Characterisation of a novel DCAF factor as a blood cancer therapy
- Prof. Maher Gandhi: Establishing a new prognostic score for Follicular Lymphoma to rationalise therapeutic decision-making and improve patient outcomes
- Prof. Peter Mollee: A better diagnosis system for AL amyloidosis
- Prof. Steven Lane: Understanding the process of progression from MDS to acute leukaemia
- The Centre for Blood Transplant and Cell Therapy
- The role of the bone marrow microenvironment in the myeloma plasma cell dormancy and reactivation – toward a cure for myeloma
- Translational Research Program Grant recipients
- Assoc. Prof. Jane Oliaro: Improving CAR-T cell therapy outcomes for patients with for aggressive lymphoma and multiple myeloma
- Dr Ashwin Unnikrishnan: Beyond Azacitidine, Investigating new therapeutic strategies for the treatment of MDS
- Dr Charles Mullighan: Improving therapy for CRLF2-rearranged Ph-like ALL
- Dr Lev Kats: Improving treatment outcomes for multiple myeloma
- Prof. John Pimanda: Optimising azacitidine (AZA) responsiveness in MDS, CMML and AML
- Prof. Ravinda Majeti, Assoc. Professor Daniel Thomas: Personalized Metabolic Targeting of Epigenetic AML Mutations
- Prof. Richard Lock: Improving outcomes for children with aggressive T-cell acute lymphoblastic leukaemia
- Prof. Ricky Johnstone: Targeting deregulated epigenetic mechanisms in B-cell lymphomas
- Prof. Stephen Nutt: Therapeutic targeting of IRF4 to treat multiple myeloma
- Cancer Australia PdCCRS recipients
- Past research
- Boosting the immune system response
- Double discovery – game changer in quest to cure leukaemia
- Graft v Host disease
- Investigating factors that may cause genetic changes in leukaemia
- New drug combination turbo charges attack against cancer
- Novel drug for treatment of Burkitt’s lymphoma
- Research project archive
- Researchers identify gene that could lead to better understanding of MDS
- Targeting stem cells in myeloproliferative disorders
- Research in action
- Research Roadmap for Blood Cancer
- Set The Standard
- Site map
- Terms of use
- Update your details
- Webinars
- Apply for the Leukaemia Foundation Breakthrough Fellowship
- Leukaemia Foundation Breakthrough Fellowships – Information
- Consumer Engagement Program News
- Graft versus host disease (GVHD)
- Our history
Last updated on September 19th, 2023
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.